The Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Monday's key moments. The Dow surged nearly 1% on Monday while the Nasdaq declined modestly as investors sold tech stocks in favor of other sectors like financials, industrials, and energy. Honeywell hit highs not seen since December 2022. Morgan Stanley and Wells Fargo climbed almost 1% and 2%, respectively. Coterra Energy shot up nearly 3%.
Eli Lilly stock climbed more than 1% on Monday after management late Friday presented positive findings regarding its GLP-1 sleep apnea trial. The data strengthens the case for GLP-1s to be used for obese patients suffering from obstructive sleep apnea. It could help expand payor coverage and further bolster demand for Lilly's offerings, which are already cleared for weight loss and treatment for diabetes.
Pharmaceuticals Technology Breaking News: Technology Breaking News: Markets Markets Investment Strategy Jim Cramer Morning Meeting Recaps Dow Jones Industrial Average Honeywell International Inc Morgan Stanley Wells Fargo & Co NASDAQ Composite Coterra Energy Inc NVIDIA Corp Microsoft Corp Eli Lilly And Co S&P 500 Index Business News
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Eli Lilly shares should be up on its latest news, plus Nvidia keeps rollingEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »